ESMO updates ESCAT framework for precision oncology: new guidance on actionability and resistance biomarkers
esmo -
AI Summary: European Society for Medical Oncology has revised its ESCAT framework, giving clinicians clearer, evidence-based guidance on which genomic and resistance biomarkers should influence treatment decisions. The update refines actionability tiers, clarifies resistance interpretation, and aims to harmonize reporting so labs and oncologists stop arguing and start treating the right patients.
Related Stories
ctDNA blood test pinpoints who needs chemo after colorectal liver surgery / 3 months
Prosigna-guided OPTIMA trial shows chemo can be safely skipped in many ER+/HER2− breast cancers / 4 months
National study to use genetic testing to guide cancer survivor follow-up / 5 months
Ultrasensitive HPV blood test detects head and neck recurrence months earlier / 4 months
Liquid biopsy blood test promises personalized lung cancer detection and monitoring / 4 months
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 3 months
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try CDC, Clinical Trials, Medical Devices, Vaccine Safety and look for the RSS link.
StackHealth Time Machine